Published in Arthritis Rheum on December 01, 1995
Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest (1996) 2.07
Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology (1998) 1.12
Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol (1997) 1.10
Human herpesvirus 6 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus. Am J Pathol (2005) 1.03
Silica exposure and altered regulation of autoimmunity. Environ Health Prev Med (2014) 1.01
Levels of soluble Fas/APO-1 in patients with Behçet's disease. Mediators Inflamm (1998) 0.87
Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clin Immunol (2010) 0.86
Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol (2002) 0.80
Use of sensitive assays to detect soluble Fas in patients with systemic lupus erythematosus: comment on the article by Knipping et al and the article by Goel et al. Arthritis Rheum (1996) 0.80
Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome. Clin Rheumatol (1998) 0.79
Elevated levels of soluble Fas in systemic lupus erythematosus: comment on the article by Knipping et al. Arthritis Rheum (1996) 0.78
The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol (2004) 0.76
Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives. Ann Rheum Dis (2001) 0.75
Ex vivo apoptosis, CD95 and CD28 expression in T cells of children with juvenile idiopathic arthritis. Rheumatol Int (2002) 0.75
Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus. Clin Rheumatol (2017) 0.75
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) (1984) 6.40
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ (2003) 4.72
Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J (1995) 4.68
Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci U S A (1984) 4.62
FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J (1997) 4.56
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51
Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med (1985) 4.47
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (1995) 3.59
Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) (1983) 3.53
The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem (1999) 3.32
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med (1998) 3.01
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem (2001) 2.94
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med (1996) 2.78
An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest (1997) 2.74
Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol (1990) 2.72
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol (2004) 2.70
Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med (1998) 2.69
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65
Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem (1999) 2.52
Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med (1987) 2.47
Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol (1993) 2.45
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest (1997) 2.32
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res (1997) 2.32
FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem (1997) 2.29
Lupus autoantibodies target ribosomal P proteins. J Exp Med (1985) 2.28
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect Immun (1997) 2.19
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood (2001) 2.15
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 2.14
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ (2001) 2.08
Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J (1994) 2.05
Specific binding of alloantigens to T cells activated in the mixed lymphocyte reaction. J Exp Med (1976) 2.04
HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J (1995) 2.01
Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ (1999) 1.99
Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol (1998) 1.96
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol (1992) 1.94
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res (2000) 1.91
Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer (1994) 1.87
Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest (1998) 1.86
Regulation of CD95/Fas signaling at the DISC. Cell Death Differ (2011) 1.86
B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines. J Exp Med (1986) 1.82
CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology (1997) 1.81
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
The Fas protein is expressed at high levels on CD4+CD8+ thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone strain, MRL lpr/lpr. Proc Natl Acad Sci U S A (1993) 1.76
Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol (1994) 1.75
Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of Schistosoma mansoni. J Exp Med (1987) 1.75
Polyarthritis in rats following the systemic injection of Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum (1983) 1.75
Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med (1984) 1.71
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ (2004) 1.62
The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest (1999) 1.58
Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum (1986) 1.58
Clonal analysis of B cells induced to secrete IgG by T cell-derived lymphokine(s). J Exp Med (1984) 1.58
The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med (1993) 1.58
Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest (1997) 1.58
A program of cell death and extracellular matrix degradation is activated in the amnion before the onset of labor. J Clin Invest (1996) 1.57
Lymphokine-induced IgM secretion by clones of neoplastic B cells. Nature (1983) 1.56
Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc Natl Acad Sci U S A (1999) 1.56
Lactobacillus casei cell wall-induced arthritis in rats: cell wall fragment distribution and persistence in chronic arthritis-susceptible LEW/N and -resistant F344/N rats. Arthritis Rheum (1984) 1.55
T cell-derived B cell growth and differentiation factors. Dichotomy between the responsiveness of B cells from adult and neonatal mice. J Exp Med (1983) 1.54
HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ (2002) 1.54
Lupus nephritis: prognostic factors in children. Pediatrics (1992) 1.51
Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation. Proc Natl Acad Sci U S A (1986) 1.51
Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 1.51
T cell receptor idiotypes are controlled by genes in the heavy chain linkage group and the major histocompatibility complex. Nature (1978) 1.51
High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood (1994) 1.50
TNF-alpha -dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci U S A (2001) 1.49
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood (1996) 1.46
Adult-onset Still's disease. Twenty-year followup and further studies of patients with active disease. Arthritis Rheum (1982) 1.45
Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest (1994) 1.45
Phosphorylation of FADD/ MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol (2000) 1.43
CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med (1995) 1.43
Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med (1998) 1.42
Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem (1998) 1.41
Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol (1998) 1.40
Vacuolating cytotoxin of Helicobacter pylori induces apoptosis in the human gastric epithelial cell line AGS. Infect Immun (2001) 1.40
Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc Natl Acad Sci U S A (1995) 1.40
Identification of the cytolinker plectin as a major early in vivo substrate for caspase 8 during CD95- and tumor necrosis factor receptor-mediated apoptosis. Mol Cell Biol (2000) 1.40
H2O2 induces monocyte apoptosis and reduces viability of Mycobacterium avium-M. intracellulare within cultured human monocytes. Infect Immun (1996) 1.39
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39
The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest (1994) 1.37